bpc-157 forum user reports BPC-157's FDA Review Raises Questions About Its Origins | American Peptide Society posted on the topic BPC-157 (Peptides, Part 2): What
Description
At about .20, a person may experience blackouts
After injection, dispose of all sharpsneedles, syringes, and lancetsin a rigid, clearly marked sharps container
Both peptides individually carry the same caveats discussed throughout this guide: limited human evidence, investigational regulatory status, and serious sourcing risk and TB-500 adds anti-doping prohibition on top
Even though the procedures were over, Daniel had a lot of homework to do
